Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07750288

Role of Dyspnea in the Progression of Pediatric Acute Respiratory Distress Syndrome

Pediatric acute respiratory distress syndrome (ARDS) is a life-threatening clinical syndrome, and dyspnea is its key symptom. Strenuous respiratory effort is a "second hit" for ARDS lungs, inducing changes in regional lung aeration and amplifying lung damage in preclinical studies, a phenomenon known as "patient self-inflicted lung injury". In a clinical setting, clinicians are concerned about the possible connection between dyspnea and ARDS progression based on indirect evidence, such as the worse outcomes associated with delayed intubation or failed weaning from mechanical ventilation. Dyspnea is hard to quantify due to its subjective nature. Still, it can be assessed through its interrelated and independent components: respiratory drive (neural stimuli), respiratory effort (muscle contraction), and work of breathing (energy expenditure).

This project aims to identify mechanical thresholds of dyspnea components to predict early ARDS progression and outcome. The role of respiratory effort is particularly relevant in three phases of ARDS where a transition between spontaneous and controlled ventilation occurs: 1) acute phase, when we try to prevent mechanical ventilation (MV) through non-invasive support; 2) intermediate phase, transitioning from controlled to assisted MV; and 3) late phase, during weaning from MV. These transitions are challenging because it is difficult for clinicians to titrate adequate support and avoid both under- and over-assistance.

In critically ill children, there are no established thresholds for dyspnea components that predict ARDS progression, and it remains unknown whether regional changes in lung aeration can anticipate this clinical deterioration. This is particularly relevant because the oxygenation decline signals that ARDS progression has already occurred, leading to a less reversible condition.

We will use and integrate advanced respiratory monitoring tools to quantify these components, including surface electromyography, occlusion maneuvers, and esophageal manometry. Additionally, electrical impedance tomography, recently adapted for pediatric use, will be employed to detect early changes in regional aeration. All tools used are gold standards for each parameter and allow real-time, bedside measurements without adding invasiveness to usual care.

To test our hypothesis, we will quantify respiratory drive, effort, work of breathing, and regional lung aeration throughout all transitional phases of pediatric ARDS. In the acute phase, drive will be assessed via spectral analysis of surface electromyography, and in intermediate and late phases, via airway occlusion pressure at 100 ms. Esophageal manometry will be used to measure effort (swings of esophageal pressure) and work of breathing (pressure-time product). Changes in regional aeration (overstretching, collapse, and heterogeneity) will be assessed using electrical impedance tomography.

We will define mechanical thresholds and cut-off points for each dyspnea component that predict early ARDS progression and outcomes at each transitional phase. Based on the study results, we envision the future development of algorithms to help guide safer transitions between spontaneous and controlled ventilation, to improve outcomes, and prevent residual morbidity. Our interdisciplinary team of clinicians and biomedical engineers will work to customize respiratory care in critically ill children, optimizing ventilatory assistance across disease stages.

Recruiting

Interested in participating?

Request Info

Key information

Age range

1 month–18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital El Carmen Dr. Luis Valentin Ferrada

Santiago, Chile

Location status: Recruiting

Location contact

Pablo Cruces, MD

CONTACT

[email protected]

(56)2266120638

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • children younger than 18 years old; 2) diagnosis of pediatric ARDS, as defined by the 2023 Pediatric Acute Lung Injury Consensus Conference (PALICC2); and 3) consent to participate given by legal guardians.

Exclusion criteria

  • tracheostomy; 2) neuromuscular disease; 3) uncorrected congenital heart diseases; 4) contraindication of esophageal catheter (choanal atresia, esophageal issues, recent esophageal surgery, etc.) or EIT (pacemakers, defibrillators, and unstable fractures). We will consider any emergency intubation as a criterion of early termination.

Treatment and study plan

Noninvasive respiratory support

Device

sEMG of respiratory muscles, esophageal manometry, and electrical impedance tomography

Transition from controlled to assisted mechanical ventilation

Device

sEMG of respiratory muscles, esophageal monitoring, and electrical impedance tomography

Weaning from mechanical ventilation

Device

sEMG of respiratory muscles, esophageal monitoring, and electrical impedance tomography

Primary outcomes

  1. Success or Failure of the Intervention

    Time frame: From enrollment to the end of respiratory support at 30 days

    Oxygenation decline (20% drop from baseline) or clinical signs of ventilatory overload. The outcome of the intervention will be determined by the attending physician. Measurements derived from the use of advanced respiratory monitoring tools will not be used to define the clinical outcome.

Secondary outcomes

  1. Early changes in regional lung aeration, perfusion, or V/Q mismatch

    Time frame: From enrollment to the end of treatment at 30 days

    Assesed by electrical impedance tomography

  2. Ventilator-free days

    Time frame: From enrollment to the end of treatment at 30 days

Other outcomes

  1. The correlation between surrogates and gold-standard assessments of respiratory drive and effort

    Time frame: From enrollment to the end of treatment at 30 days

Study contacts

Contact information is provided by the study sponsor or research team.

Pablo Cruces, Full Professor

CONTACT

[email protected]

(56)990200810

Sponsors and collaborators

Lead sponsor

Universidad Nacional Andres Bello

Other

Collaborators

  • Pontificia Universidad Catolica de Chile
  • Universidad de los Andes, Chile

Registry information

Important dates

Study start
2026
Primary completion
2030
Study completion
2030
First posted
Aug 6, 2026
Registry last updated
Aug 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.